{
    "root": "4e9b454f-716f-4eef-9717-62226d0d4f09",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Sertraline Hydrochloride",
    "value": "20250310",
    "ingredients": [
        {
            "name": "SERTRALINE HYDROCHLORIDE",
            "code": "UTI8907Y6X"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (1600000 WAMW)",
            "code": "RFW2ET671P"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "VANILLIN",
            "code": "CHI530446X"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "sertraline hydrochloride tablets indicated treatment following [ ( 14 ) ] : major depressive disorder ( mdd ) obsessive-compulsive disorder ( ocd ) panic disorder ( pd ) posttraumatic stress disorder ( ptsd ) social anxiety disorder ( sad ) premenstrual dysphoric disorder ( pmdd )",
    "contraindications": "indication starting maximum mdd ( 2.1 ) 50 mg per day 200 mg per day ocd ( 2.1 ) 25 mg per day ( ages 6 12 ) 200 mg per day 50 mg per day ( ages \u2265 13 ) pd , ptsd , sad ( 2.1 ) 25 mg per day 200 mg per day pmdd ( 2.2 ) continuous dosing 50 mg per day 150 mg per day pmdd ( 2.2 ) intermittent dosing 50 mg per day luteal phase 100 mg per day luteal phase inadequate response starting , titrate 25 50 mg per day increments weekly mdd , ocd , pd , ptsd , sad ( 2.1 ) full prescribing information titration pmdd ( 2.2 ) hepatic impairment : mild : recommended starting maximum half recommended ( 2.4 ) moderate severe : recommended ( 2.4 ) discontinuing sertraline hydrochloride tablets , reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions": "sertraline hydrochloride tablets usp , 25 mg green colored , capsule shaped , biconvex , film-coated tablets , debossed ' l ' ' u ' either side breakline one side 'd01 ' side . ndc 68180-351-06 bottles 30 ndc 68180-351-09 bottles 90 ndc 68180-351-03 bottles 1000 sertraline hydrochloride tablets usp , 50 mg blue colored , capsule shaped , biconvex , film-coated tablets , debossed ' l ' ' u ' either side breakline one side 'd02 ' side . ndc 68180-352-06 bottles 30 ndc 68180-352-09 bottles 90 ndc 68180-352-02 bottles 500 ndc 68180-352-05 bottles 5000 sertraline hydrochloride tablets usp , 100 mg yellow colored , capsule shaped , biconvex , film-coated tablets , debossed ' l ' ' u ' either side breakline one side 'd03 ' side . ndc 68180-353-06 bottles 30 ndc 68180-353-09 bottles 90 ndc 68180-353-02 bottles 500 ndc 68180-353-05 bottles 5000 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "sertraline hydrochloride tablets contraindicated patients : taking , within 14 days stopping , maois , ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.2 ) , ( 7.1 ) ] . taking pimozide [ ( 7.1 ) ] . known hypersensitivity sertraline ( e.g . , anaphylaxis , angioedema ) [ ( 6.1 , 6.2 ) ] .",
    "indications_original": "Sertraline hydrochloride tablets are indicated for the treatment of the following [See Clinical Studies (14)]:\n                  \n                     Major      depressive disorder (MDD)\n                     Obsessive-compulsive      disorder (OCD)\n                     Panic disorder      (PD)\n                     Posttraumatic      stress disorder (PTSD)\n                     Social anxiety      disorder (SAD)\n                     Premenstrual dysphoric disorder (PMDD)",
    "contraindications_original": "Indication Starting Dosage Maximum Dosage MDD (2.1) 50 mg per day 200 mg per day OCD (2.1) 25 mg per day (ages 6 to 12) 200 mg per day 50 mg per day (ages \u2265 13) PD, PTSD, SAD (2.1) 25 mg per day 200 mg per day PMDD (2.2) continuous dosing 50 mg per day 150 mg per day PMDD (2.2) intermittent dosing 50 mg per day during luteal phase only 100 mg per day during luteal phase only If inadequate response to starting dosage, titrate in 25 to 50 mg per day increments once weekly in MDD, OCD, PD, PTSD, and SAD ( 2.1 ) See Full Prescribing Information for titration in PMDD ( 2.2 ) Hepatic impairment: Mild: Recommended starting and maximum dosage is half recommended dosage ( 2.4 ) Moderate or severe: Not recommended ( 2.4 ) When discontinuing sertraline hydrochloride tablets, reduce dose gradually ( 2.6 , 5.4 )",
    "warningsAndPrecautions_original": "Sertraline Hydrochloride Tablets USP, 25 mg\n                  \n                  Green colored, capsule shaped, biconvex, film-coated tablets, debossed with 'L' and 'U' on either side of the breakline on one side and 'D01' on the other side.\n                  NDC 68180-351-06\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 30\n                  NDC 68180-351-09\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 90\n                  NDC 68180-351-03\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 1000\n                  \n                     Sertraline Hydrochloride Tablets USP, 50 mg\n                  \n                  Blue colored, capsule shaped, biconvex, film-coated tablets, debossed with 'L' and 'U' on either side of the breakline on one side and 'D02' on the other side.\n                  NDC 68180-352-06\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 30\n                  NDC 68180-352-09\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 90\n                  NDC 68180-352-02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 500\n                  NDC 68180-352-05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 5000\n                  \n                     Sertraline Hydrochloride Tablets USP, 100 mg\n                  \n                  Yellow colored, capsule shaped, biconvex, film-coated tablets, debossed with 'L' and 'U' on either side of the breakline on one side and 'D03' on the other side.\n                  NDC 68180-353-06\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 30\n                  NDC 68180-353-09\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 90\n                  NDC 68180-353-02\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 500\n                  NDC 68180-353-05\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Bottles of 5000\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [See USP Controlled Room Temperature].",
    "adverseReactions_original": "Sertraline hydrochloride tablets are contraindicated in patients:\n                  \n                     Taking, or within 14 days of      stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene      blue) because of an increased risk of serotonin syndrome [See Warnings      and Precautions (5.2), Drug Interactions (7.1)] .\n                     Taking pimozide [See Drug      Interactions (7.1)].\n                     \n                     With known      hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [See      Adverse Reactions (6.1, 6.2)] ."
}